Defunct Company
Total Trials
5
As Lead Sponsor
As Collaborator
0
Total Enrollment
225
NCT06873542
A Study of DC05F01 in Chinese Patients with Advanced or Metastatic Solid Tumors
Phase: Phase 1
Role: Lead Sponsor
Start: Jul 8, 2022
Completion: Jan 2, 2024
NCT06860282
A Study of CX2101A Enteric-Coated Tablets in Healthy Chinese Adult Subjects
Start: Dec 26, 2022
Completion: Mar 27, 2023
NCT06864182
Relative Bioavailability Study of CX2101A for the Treatment of COVID-19
Start: Mar 21, 2024
Completion: May 25, 2024
NCT06873555
A Study of DC05F01 in Chinese Patients with Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
Phase: Phase 1/2
Start: Sep 11, 2024
Completion: Aug 31, 2026
NCT07071090
A Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
Start: Jun 30, 2025
Completion: Jan 1, 2028